http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110092787-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110092787-B |
| titleOfInvention | Preparation and application of compound or medicinal salt or composition thereof |
| abstract | The invention relates to tricyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for inhibiting Epidermal Growth Factor Receptor (EGFR) kinase mutants, such as EGFR (del E746-A750), EGFR (L858R), EGFR (del E746-A750/T790M), EGFR (L858R/T790M), and EGFR exon 20insertion, and the like, and thus are useful for treating cancers caused by EGFR mutants, such as non-small cell lung cancer. The invention also relates to pharmaceutical compositions containing such compounds, to processes for preparing such compounds and to the use of such compounds or pharmaceutical compositions for the preparation of medicaments for the treatment of cancer caused by EGFR mutants. |
| priorityDate | 2018-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.